ALMS

Business Context and Reporting Period

Company: Alumis Inc. (ALMS)
Filing Type: Form 10-K (Annual Report)
Reporting Period: Fiscal year ended December 31, 2024
Business Overview: Alumis is a clinical-stage biopharmaceutical company focused on developing targeted therapies for immune-mediated diseases. Its primary assets are two Tyrosine Kinase 2 (TYK2) inhibitors: ESK-001 (for psoriasis and systemic lupus erythematosus) and A-005 (a CNS-penetrant molecule for neuroinflammatory diseases like multiple sclerosis). The company has no approved products and has not generated any revenue from product sales.

Key Financial Metrics

Note: The filing does not provide specific margin data as the company has no revenue. Debt levels are not explicitly detailed as a line item in the summary tables, though the company relies on equity financing.

Material Changes vs. Prior Period

• Increased Losses: Net loss increased by 90% to $294.2 million in 2024 compared to $155.0 million in 2023, driven primarily by accelerated clinical development.
• R&D Expense Surge: R&D expenses rose 93% to $265.6 million. Key drivers included a $23.0 million milestone payment for the FronThera acquisition and a 120% increase in CRO/CMO and clinical trial costs ($151.4 million) due to the advancement of ESK-001 and A-005.
• Capital Raise: The company completed an Initial Public Offering (IPO) in July 2024, raising net proceeds of $193.3 million, and a concurrent private placement raising $40.0 million. This significantly increased cash reserves from $47.1 million at the end of 2023 to $288.3 million at the end of 2024.
• Stock-Based Compensation: Increased to $19.5 million in 2024 from $8.6 million in 2023, reflecting new equity plans adopted in connection with the IPO.

Guidance, Outlook, and Risks

Merger with ACELYRIN: On February 6, 2025, Alumis entered into a merger agreement with ACELYRIN, Inc. The transaction is an all-stock deal where ACELYRIN shareholders will receive 0.4274 shares of Alumis stock for each share held. Post-merger, pre-merger Alumis shareholders are expected to own approximately 55% of the combined company. The merger is subject to stockholder approval and other closing conditions, with a termination date of July 7, 2025.

Clinical Outlook:

• ESK-001: Phase 3 ONWARD trials in psoriasis are ongoing, with topline results expected in Q1 2026. A Phase 2b trial in systemic lupus erythematosus (SLE) is ongoing, with results expected in 2026.
• A-005: Phase 1 results in healthy volunteers were reported in December 2024. The program targets multiple sclerosis and other neuroinflammatory diseases.

Going Concern Warning: Management has concluded there is substantial doubt about the company's ability to continue as a going concern. Despite the recent capital raise, existing cash resources ($288.3 million) are not sufficient to meet operating and capital requirements for at least 12 months from the date of the financial statements. Additional financing will be required.

Key Risks:

• Failure to complete the ACELYRIN merger.
• Substantial and increasing losses with no revenue.
• Uncertainty of clinical trial outcomes and regulatory approval.
• Need for substantial additional financing.

Investor Verification Checklist

• Merger Status: Verify the progress of the ACELYRIN merger, including stockholder approval status and any potential termination fees ($10.0 million).
• Cash Runway: Confirm the company's updated cash burn rate and specific timeline for the next capital raise, given the "substantial doubt" going concern warning.
• Clinical Milestones: Monitor the timeline for Phase 3 topline data for ESK-001 (expected Q1 2026) and the safety/efficacy data for A-005.
• Contingent Liabilities: Review the remaining potential milestone payments under the FronThera acquisition agreement (up to $97 million remaining).
• Stock Dilution: Assess the dilution impact of the merger exchange ratio and future equity financings required to fund operations.